NLS Pharmaceutics Provides Open Label Extension Study Update for Quilience(R) (Mazindol ER) in the Treatment of Narcolepsy
NLS Pharmaceutics Ltd. - Common Shares (NLSP)
Company Research
Source: Accesswire
Patients treated with Quilience® in the randomized Phase 2 trial continue to improve after rolling over into the open label extension (OLE) studyPlacebo patients in the randomized Phase 2 trial who received Quilience® in the OLE study achieved comparable results to treated patients in the Phase 2 trialSafety and tolerability of Quilience® were similar between the randomized trial and OLEZURICH, SWITZERLAND / ACCESSWIRE / November 7, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces an interim update from its Open Label Extension (OLE) Study for Quilience® (Mazindol ER) in the treatment of narcolepsy. The OLE study offers patients completing the 4-week randomized, double blind (DB) Phase 2 trial for Quilience® the option to receive the drug candidate for an additional 6
Show less
Read more
Impact Snapshot
Event Time:
NLSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NLSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NLSP alerts
High impacting NLS Pharmaceutics Ltd. - Common Shares news events
Weekly update
A roundup of the hottest topics
NLSP
News
- NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing [Yahoo! Finance]Yahoo! Finance
- NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request HearingAccesswire
- NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering [Yahoo! Finance]Yahoo! Finance
- NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering Accesswire
- NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering [Yahoo! Finance]Yahoo! Finance
NLSP
Sec Filings
- 4/30/24 - Form NT
- 4/19/24 - Form 6-K
- 4/15/24 - Form 6-K
- NLSP's page on the SEC website